trending Market Intelligence /marketintelligence/en/news-insights/trending/efE4XIYIuItgPpDqcCoGBg2 content esgSubNav
In This List

Aura completes acquisition of 80% stake in German medical cannabis distributor

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Aura completes acquisition of 80% stake in German medical cannabis distributor

Canadian cannabis company Aura Health Inc. completed its planned acquisition of an 80% equity interest in Pharmadrug Production GmbH from Anquor Pharmaceuticals UG for €5 million.

Aura inked a definitive deal to acquire the German medical cannabis distributor in late February. German pharmaceutical products supplier Anquor Pharmaceuticals retained a 20% interest in Pharmadrug.

Pharmadrug holds a narcotics license in the EU, which allows it to distribute pharmaceutical products and medical cannabis to German pharmacies and the rest of the eurozone as markets become legalized.

The transaction will help Aura export its own medical cannabis from Israel into the EU. The company also plans to grow the Pharmadrug business through additional supply agreements with other Canadian, European and Israeli licensed producers.